RNA
NASDAQAtrium Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks41+1100%
2026-04-192026-10-11
Mix2390d
- Insider8(35%)
- Other7(30%)
- SEC Filings4(17%)
- Earnings3(13%)
- Analyst1(4%)
Latest news
25 items- SECAmendment: SEC Form 8-K/A filed by Atrium Therapeutics Inc.8-K/A - Atrium Therapeutics, Inc. (0002093101) (Filer)
- SECSEC Form 8-K filed by Atrium Therapeutics Inc.8-K - Atrium Therapeutics, Inc. (0002093101) (Filer)
- PRAtrium Therapeutics Announces $50 Million Private PlacementSAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) ("Atrium" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it has entered into a securities purchase agreement (the "purchase agreement") with a group of leading institutional investors for a private placement financing (the "private placement"). The private placement is expected to result in aggregate gross proceeds to the Company of approximately $50 million, before deducting placement agent fees and other offering expenses.The private placement includes participation from Sirenia Capital Management LP, Aberde
- INSIDERChief Scientific Officer Younis Husam covered exercise/tax liability with 11,216 shares, decreasing direct ownership by 21% to 41,441 units (SEC Form 4) to cover taxes4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)
- INSIDERChief Medical Officer Hughes Steven George covered exercise/tax liability with 21,459 shares, decreasing direct ownership by 29% to 51,638 units (SEC Form 4) to satisfy withholding tax4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)
- INSIDERDirector Boyce Sarah covered exercise/tax liability with 126,418 shares, decreasing direct ownership by 48% to 138,668 units (SEC Form 4) (withholding obligation)4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)
- INSIDERDirector Flanagan W. Michael covered exercise/tax liability with 22,812 shares, decreasing direct ownership by 42% to 31,974 units (SEC Form 4) to satisfy withholding tax4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)
- INSIDEROfficer Kenney Stephanie covered exercise/tax liability with 2,375 shares, decreasing direct ownership by 7% to 33,085 units (SEC Form 4) to satisfy withholding tax4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)
- INSIDERChief Financial Officer Winslow Brendan R. covered exercise/tax liability with 6,742 shares, decreasing direct ownership by 15% to 36,859 units (SEC Form 4) (for withholding tax)4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)
- INSIDEROfficer Gallagher Kathleen P. covered exercise/tax liability with 11,632 shares, decreasing direct ownership by 9% to 119,729 units (SEC Form 4) (for tax liability)4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)
- INSIDERChief Strategy Officer Hoyos Rocio Martin covered exercise/tax liability with 8,320 shares, decreasing direct ownership by 18% to 38,340 units (SEC Form 4) to satisfy withholding obligation4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)
- PRAtrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company") today announced it awarded inducement grants on September 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company. The employee received, in the aggregate, non-qualified stock options to purchase 13,500 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $8.95 per share, the closing price of the Company's common stock as reported by Nasdaq on t
- PRAtrium Therapeutics to Participate in Upcoming Investor ConferencesSAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it will participate in upcoming investor conferences in September. Since its launch earlier this year, Atrium has made meaningful progress including U.S. Food and Drug Administration (FDA) clearance of the Company's Investigational New Drug (IND) application for ATR-1072 for the treatment of PRKAG2 syndrome, receipt of a No Objection Letter from Health Canada, the launch of the Corventis™ Phase 1/2 clinical trial, an
- PRAtrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Aug. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company") today announced it awarded inducement grants on August 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company. The employee received, in the aggregate, non-qualified stock options to purchase 11,000 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $13.48 per share, the closing price of the Company's common stock as reported by Nasdaq on the
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Atrium Therapeutics Inc.SCHEDULE 13G/A - Atrium Therapeutics, Inc. (0002093101) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Atrium Therapeutics Inc.SCHEDULE 13G/A - Atrium Therapeutics, Inc. (0002093101) (Subject)
- SECSEC Form 10-Q filed by Atrium Therapeutics Inc.10-Q - Atrium Therapeutics, Inc. (0002093101) (Filer)
- SECAtrium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Atrium Therapeutics, Inc. (0002093101) (Filer)
- PRAtrium Therapeutics Reports Second Quarter 2026 Financial Results-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome ---- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb --SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) ("Atrium," "Atrium Therapeutics," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate progress including FDA clearance of its Investigational New Drug (IND) application for ATR 1072 and continued achievements under its collaboration
- PRAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular CollaborationSAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, today announced it has earned another $15 million milestone payment from Bristol Myers Squibb (NYSE:BMY) based on the successful delivery of a lead compound targeting an undisclosed cardiology indication under the Company's ongoing collaboration. "Atrium's vision is to deliver treatments that address the underlying cause of serious heart disease, including rare genetic cardiomyopathies," said Kathleen Gallagher, Pres
- ANALYSTH.C. Wainwright initiated coverage on Atrium Therapeutics with a new price targetH.C. Wainwright initiated coverage of Atrium Therapeutics with a rating of Buy and set a new price target of $25.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Atrium Therapeutics Inc.SCHEDULE 13G/A - Atrium Therapeutics, Inc. (0002093101) (Subject)
- PRAtrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, July 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company") today announced it awarded inducement grants on July 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company. The employee received, in the aggregate, non-qualified stock options to purchase 7,000 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $11.76 per share, the closing price of the Company's common stock as reported by Nasdaq on the eff
- SECSEC Form 8-K filed by Atrium Therapeutics Inc.8-K - Atrium Therapeutics, Inc. (0002093101) (Filer)
- PRAtrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome-- ATR 1072 is the company's first precision cardiology program to enter the clinic ---- Corventis™ will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential treatment for the underlying cause of the disease --SAN DIEGO, July 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application allowing the Company to move forward with its Corventis™ Phase 1/2 clinical trial designed to evaluate ATR 1072 for the treatment of Protein Kina
RNA FAQ
6 questionsWhat does Atrium Therapeutics Inc. do?
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying...Where does RNA stock trade?
Atrium Therapeutics Inc. (RNA) is listed on NASDAQ.What sector and industry is RNA in?
Atrium Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about RNA?
Atrium Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $2500.00 price target on 2026-08-06. Recent price targets cluster around $2500.00.What companies are similar to RNA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RNA side-by-side with any of them on Quantisnow.How can I track RNA on Quantisnow?
Quantisnow aggregates Atrium Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RNA to receive live email and push alerts on every new disclosure.